Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.43 for the year, down from their prior forecast of $0.46. HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' FY2029 earnings at $1.81 EPS.
Milestone Pharmaceuticals Price Performance
Shares of Milestone Pharmaceuticals stock traded down $0.05 on Wednesday, reaching $1.90. 2,242,755 shares of the stock were exchanged, compared to its average volume of 452,640. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The firm has a market cap of $101.37 million, a PE ratio of -2.35 and a beta of 1.83. The firm's 50 day moving average is $2.01 and its 200-day moving average is $1.82. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75.
Institutional Investors Weigh In On Milestone Pharmaceuticals
A number of large investors have recently modified their holdings of the business. Atria Investments Inc grew its position in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company's stock valued at $61,000 after acquiring an additional 12,430 shares during the last quarter. PVG Asset Management Corp acquired a new position in Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Jones Financial Companies Lllp lifted its stake in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at approximately $170,000. Finally, National Bank of Canada FI grew its stake in shares of Milestone Pharmaceuticals by 163.4% during the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after buying an additional 11,600 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company's stock.
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
See Also
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
